Average change in quality of life/satisfaction · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life/satisfaction with care for either recipients of care or carers: significant change in quality of life/satisfaction · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically significant response on psychotic symptoms ‐ as defined by each of the studies. · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: 1. Sedation · patients with schizophrenia
It is very uncertain whether ZUCLOPENTHIXOL DIHYDROCHLORIDE changes adverse effects: Sedation compared with PLACEBO (very low certainty).
1 finding from 1 review
Average change in quality of life/satisfaction · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life/satisfaction with care for either recipients of care or carers: significant change in quality of life/satisfaction · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically significant response on global state · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: No clinically important change (as defined by the original studies) · adults with schizophrenia
ASENAPINE may leads to lower global state: No clinically important change CGI‐I compared with PLACEBO (low certainty).
1 finding from 1 review
Clinical response: no clinically significant response in mental state · adults with schizophrenia
It is very uncertain whether ASENAPINE changes mental state: No clinically important change PANSS compared with PLACEBO (very low certainty).
1 finding from 1 review
Mental state: Average change score in negative symptoms PANSS Marder negative factor score · adults with schizophrenia
1 finding from 1 review
Adverse effects: Incidence of serious adverse effects · adults with schizophrenia
It is very uncertain whether ASENAPINE changes adverse effects: Incidence of serious adverse effects compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · adults with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · adults with schizophrenia
It is very uncertain whether ASENAPINE changes leaving the study early ‐ any reason compared with PLACEBO (very low certainty).
1 finding from 1 review
Costs · adults with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · patients with schizophrenia
1 finding from 1 review
Relapse · patients with schizophrenia
It is very uncertain whether CHLORPROMAZINE changes relapse compared with PLACEBO (very low certainty).
1 finding from 1 review
Global state: no overall improvement (psychiatrist ‐ rated) · patients with schizophrenia
It is very uncertain whether CHLORPROMAZINE changes global state: no overall improvement (psychiatrist ‐ rated) compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
CHLORPROMAZINE may leads to lower leaving the study early compared with PLACEBO (low certainty).
1 finding from 1 review
Satisfaction with treatment ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found